Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130073663> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3130073663 endingPage "102787" @default.
- W3130073663 startingPage "102787" @default.
- W3130073663 abstract "Double-positive patients (DPP) exhibiting anti-glomerular basement membrane (GBM) and anti-neutrophil cytoplasmic antibodies (ANCAs) belong to an entity that is newly and poorly described, mainly in short series. We aimed to better characterize the epidemiological features, clinical presentation and therapeutic outcomes of these patients through a systematic review.We performed a systematic review of English-, German-, Spanish- and French-written publications from February 1987 to March 2020 reporting cases of DPP using the following databases: PubMed, Scielo, ScienceDirect, Google Scholar, The Cochrane Library, Open Grey, The Grey Literature Report, Clinicaltrials.gov and International Clinical Trial Registry Platform of the World Health Organization.In total, 538 DPP were identified from 90 articles. Their clinical presentations were often severe, and the majority exhibited acute kidney failure (91.8%) with a median initial serum creatinine level of 873 μmol/L; 50.7% had alveolar haemorrhage. Other manifestations were present in 30.3% of DPP, mainly ear, nose, throat and articular manifestations. ANCAs were predominantly directed against MPO (n = 377/523; 72.1%) compared to PR3 (n = 107/523; 20.5%), with rare cases of triple positivity (n = 15/538; 2.9%). Although most patients received initial immunosuppressive therapy (n = 285/317; 89.9%), the one-year overall, renal and relapse-free survival rates were 64.8%, 38.7% and 71.1%, respectively.DPP are associated with the characteristics of two eponymous vasculitis types, responsible for a poor overall and renal prognosis. Thus, simultaneous testing of both antibodies and systematic renal biopsy should be recommended in every patient with rapidly progressive glomerulonephritis to recognize this difficult-to-treat and rare disease." @default.
- W3130073663 created "2021-03-01" @default.
- W3130073663 creator A5018377091 @default.
- W3130073663 creator A5029075217 @default.
- W3130073663 creator A5029721718 @default.
- W3130073663 creator A5060856636 @default.
- W3130073663 date "2021-04-01" @default.
- W3130073663 modified "2023-10-14" @default.
- W3130073663 title "Anti-neutrophil cytoplasm antibodies (ANCA) in autoimmune diseases: A matter of laboratory technique and clinical setting" @default.
- W3130073663 cites W1965911418 @default.
- W3130073663 cites W1972386437 @default.
- W3130073663 cites W1973849425 @default.
- W3130073663 cites W1990570118 @default.
- W3130073663 cites W2000959749 @default.
- W3130073663 cites W2022310238 @default.
- W3130073663 cites W2054597879 @default.
- W3130073663 cites W2096252344 @default.
- W3130073663 cites W2121421374 @default.
- W3130073663 cites W2140880392 @default.
- W3130073663 cites W2156877459 @default.
- W3130073663 cites W2765131058 @default.
- W3130073663 cites W2983355794 @default.
- W3130073663 cites W3006519940 @default.
- W3130073663 cites W3013626875 @default.
- W3130073663 cites W3037708183 @default.
- W3130073663 cites W3041655488 @default.
- W3130073663 cites W3087336541 @default.
- W3130073663 doi "https://doi.org/10.1016/j.autrev.2021.102787" @default.
- W3130073663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33609803" @default.
- W3130073663 hasPublicationYear "2021" @default.
- W3130073663 type Work @default.
- W3130073663 sameAs 3130073663 @default.
- W3130073663 citedByCount "5" @default.
- W3130073663 countsByYear W31300736632021 @default.
- W3130073663 countsByYear W31300736632022 @default.
- W3130073663 crossrefType "journal-article" @default.
- W3130073663 hasAuthorship W3130073663A5018377091 @default.
- W3130073663 hasAuthorship W3130073663A5029075217 @default.
- W3130073663 hasAuthorship W3130073663A5029721718 @default.
- W3130073663 hasAuthorship W3130073663A5060856636 @default.
- W3130073663 hasConcept C126322002 @default.
- W3130073663 hasConcept C24040308 @default.
- W3130073663 hasConcept C2776015282 @default.
- W3130073663 hasConcept C2779134260 @default.
- W3130073663 hasConcept C2780306776 @default.
- W3130073663 hasConcept C535046627 @default.
- W3130073663 hasConcept C71924100 @default.
- W3130073663 hasConcept C90924648 @default.
- W3130073663 hasConceptScore W3130073663C126322002 @default.
- W3130073663 hasConceptScore W3130073663C24040308 @default.
- W3130073663 hasConceptScore W3130073663C2776015282 @default.
- W3130073663 hasConceptScore W3130073663C2779134260 @default.
- W3130073663 hasConceptScore W3130073663C2780306776 @default.
- W3130073663 hasConceptScore W3130073663C535046627 @default.
- W3130073663 hasConceptScore W3130073663C71924100 @default.
- W3130073663 hasConceptScore W3130073663C90924648 @default.
- W3130073663 hasIssue "4" @default.
- W3130073663 hasLocation W31300736631 @default.
- W3130073663 hasLocation W31300736632 @default.
- W3130073663 hasOpenAccess W3130073663 @default.
- W3130073663 hasPrimaryLocation W31300736631 @default.
- W3130073663 hasRelatedWork W179552849 @default.
- W3130073663 hasRelatedWork W2028189322 @default.
- W3130073663 hasRelatedWork W2070931144 @default.
- W3130073663 hasRelatedWork W2079913949 @default.
- W3130073663 hasRelatedWork W2080567030 @default.
- W3130073663 hasRelatedWork W2135023588 @default.
- W3130073663 hasRelatedWork W2149186796 @default.
- W3130073663 hasRelatedWork W2162386649 @default.
- W3130073663 hasRelatedWork W2398608410 @default.
- W3130073663 hasRelatedWork W2903985700 @default.
- W3130073663 hasVolume "20" @default.
- W3130073663 isParatext "false" @default.
- W3130073663 isRetracted "false" @default.
- W3130073663 magId "3130073663" @default.
- W3130073663 workType "article" @default.